196 related articles for article (PubMed ID: 25799952)
21. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
22. Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation.
Grigsby JG; Parvathaneni K; Almanza MA; Botello AM; Mondragon AA; Allen DM; Tsin AT
J Ocul Pharmacol Ther; 2011 Jun; 27(3):225-33. PubMed ID: 21413859
[TBL] [Abstract][Full Text] [Related]
23. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
[TBL] [Abstract][Full Text] [Related]
24. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
25. A study on platinum(iv) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer.
Hu W; Zhao J; Hua W; Gou S
Metallomics; 2018 Feb; 10(2):346-359. PubMed ID: 29349448
[TBL] [Abstract][Full Text] [Related]
26. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
27. NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity.
Kim HI; Kim T; Kim JE; Lee J; Heo J; Lee NR; Kim NJ; Inn KS
Int J Oncol; 2015 Jul; 47(1):280-6. PubMed ID: 25964080
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
29. Antitumor mechanism of action of a cyclopropyl antiestrogen (compound 7b) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Cancer Chemother Pharmacol; 1996; 38(3):238-44. PubMed ID: 8646798
[TBL] [Abstract][Full Text] [Related]
30. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.
Blackwell KL; Haroon ZA; Shan S; Saito W; Broadwater G; Greenberg CS; Dewhirst MW
Clin Cancer Res; 2000 Nov; 6(11):4359-64. PubMed ID: 11106254
[TBL] [Abstract][Full Text] [Related]
32. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
33. The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.
Chuang IC; Yang CM; Song TY; Yang NC; Hu ML
Life Sci; 2015 Oct; 139():52-61. PubMed ID: 26285173
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human umbilical vein endothelial cells.
Toth B; Scholz C; Saadat G; Geller A; Schulze S; Mylonas I; Friese K; Jeschke U
Acta Histochem; 2009; 111(6):508-19. PubMed ID: 19004482
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
de Medina P; Payré BL; Bernad J; Bosser I; Pipy B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1165-73. PubMed ID: 14617686
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
Jameera Begam A; Jubie S; Nanjan MJ
Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582
[TBL] [Abstract][Full Text] [Related]
37. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Sharma D; Saxena NK; Davidson NE; Vertino PM
Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
[TBL] [Abstract][Full Text] [Related]
38. Are estrogen receptor content in breast cancer and effects of tamoxifen on sex hormone-binding globulin markers for individual estrogen sensitivity?
Löfgren L; von Schoultz E; Fernstad R; von Schoultz B; Carlström K
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):76-9. PubMed ID: 16621526
[TBL] [Abstract][Full Text] [Related]
39. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
40. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
